Drugs.com - Clinical Trials

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

FOSTER CITY, Calif.--(BUSINESS WIRE) May 7, 2025 -- Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV)...

May 14, 2025 - 01:28
 0
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE) May 7, 2025 -- Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV)...
Read More

Tags:

Previous Article

In New SELECT Trial Analysis, Early Reduction in Cardiovascular Events Was Obser...

Next Article

US puts sanctions on companies alleged to be shipping Iranian oil to China

Related Posts

In New SELECT Trial Analysis, Early Reduction in Cardiovascular Events Was Observed with Wegovy®, Before Clinically Meaningful Changes in Body Weight

In New SELECT Trial Analysis, Early Reduction in Cardio...

May 14, 2025  0

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Boehringer’s New Zongertinib Data Demonstrates Durable ...

May 12, 2025  0

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

May 12, 2025  0